Safety and Efficacy of the 4MD Micro Needling Device in the Treatment of Acne Scars

Acne Scarring Clinical Trial

Official title:

Safety and Efficacy of the 4MD Microneedling Device in the Treatment of Acne Scars

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT05386732
• Other study ID #: Derma_01 1482-N-20
• Status: Completed
• Start date: June 19, 2020
• Est. completion date: October 9, 2020

Study information

• Verified date: May 2022
• Source: Dermapenworld
• Contact: n/a
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

The objective of this post market clinical follow-up study is to assess the safety and effectiveness of the 4MD microneedling device in reducing scarring of atrophic acne scars.

The Primary endpoint was to show a reduction in acne scarring in accordance with the Acne Scar Assessment Scale as used by Skinpen (Bellus Medical (DEN160029)).

Goodman and Baron and Jacob acne scar assessment and classification will also be utilized Safety endpoint: incidence of adverse events and side effects

Description:

This is a post market study involving 22 healthy patients. Screening data was reviewed to determine eligibility. After informed consent, confidentiality and photographic release forms, participants who meet all inclusion criteria and none of the exclusion criteria were entered into the study. Each patient underwent 2 micro needling sessions 4 weeks apart using the 4MD microneedling device and individual sterile microneedling cartridge (16, 3mm, 33-gauge surgical grade stainless steel needles, arranged in a circular pattern) Patients were assessed at baseline and at week 8. If the assessing physician deemed a 3rd treatment was necessary, the patient underwent the third treatment and would be assessed 4 weeks after the 3rd microneedling treatment Routine VECTRA photography was taken at Baseline, and at the final assessment (4 weeks after what was deemed the last treatment).

Patients' VECTRA photography was used to assess acne scarring at baseline and 4 weeks after the last treatment using the Acne Scar Assessment Scale (DEN160029) by Karnick et al. Assessment was carried out by the principle investigator and 2 blinded physicians.

After each treatment, patients completed a treatment experience assessment and patient diaries including self-assessment of side effects from the day of the treatment to day 7.

The number, type, and severity of adverse events were recorded during the duration of the study period.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 22
• Est. completion date: October 9, 2020
• Est. primary completion date: October 9, 2020
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: 18 Years to 65 Years

Eligibility

Inclusion Criteria:

• Healthy male & females; 18 to 65 years of age with signs of post-acne facial atrophic scarring.

• Voluntary participation

• Ability to comprehend and provide informed consent.

• Participants agree NOT to use any topical agents containing active ingredients such as retinol, glycolic acid or products that will induce skin peeling or change the appearance of acne scars in the treatment area, during the study period.

• Participants agree NOT to undergo any aesthetic treatments that influence appearing of acne scarring (such as Botox, fillers, microdermabrasion, laser surfacing, chemical peels etc.) in the treatment area, during the study period.

• Participants agree NOT to take part in another clinical study or undergo other treatments during the study period.

Exclusion Criteria:

• Haemophilia / bleeding disorder

• Uncontrolled diabetes mellitus

• Treatment of eyeball or mucosa

• Treatment of skin area with dermatosis, e.g. skin tumor, keloid (or extreme keloidal tendency), solar keratosis, warts, or birth marks

• Anticoagulant therapy, e.g. warfarin, heparin, salicylic acid

• Chemotherapy, radiotherapy, or high doses of corticosteroids

• Systemic infection (e.g. hepatitis) or acute skin infection (e.g. herpes)

• Any form of active acne

• Allergic reaction to topical and local anesthetics

• Pregnancy and lactation

• Eczema, exanthema or open wounds

• Scars not older than 6 months

• Skin area with plastic surgery in the past 12 months

• Skin area with filler or Botox injections in the past 6 months.

Related Conditions & MeSH terms

• Acne Scarring
• Cicatrix

Intervention

Device:
• Micro needling
All patients were treated with a 16 needle, 3mm, 33-gauge surgical grade stainless steel needle cartridge. The operator began treatment using a depth of (1mm) and a frequency setting of 4 (corresponding to 120 Hz). Needle depth and frequency was adjusted until pin-point bleeding occured, the minimum and maximum depth used to create pinpoint bleeding was recorded. The operator began treatment using a minimum depth of 1mm and a frequency setting of 4 (corresponding to 120 Hz). Needle depth and frequency was adjusted until pin-point bleeding occurred.

Locations

Country	Name	City	State
Spain	Dr Gabriela Casabona	Marbella

Sponsors (1)

Lead Sponsor	Collaborator
Dermapenworld

Country where clinical trial is conducted

Spain, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Demonstrate a reduction in acne scarring in accordance with the Acne Scar Assessment Scale (DEN160029) 4 weeks after last treatment versus baseline (first treatment).	Demonstrate a reduction in acne scarring in accordance with the Acne Scar Assessment Scale (DEN160029) 4 weeks after last treatment versus baseline (first treatment).; Scale is a 5 point scale where 0 is no acne scarring and 5 is all or almost all acne scars can be seen with direct lighting.	4 weeks after last treatment versus baseline (first treatment).
Secondary	The time in which redness, pain, and discomfort after treatment decreases.	The time in which redness, pain, and discomfort after treatment decreases.	4 weeks